There was also the proposed merger between Coepti

There was also the proposed merger between Coeptis & CURE Pharma in Nov. 2019
https://curepharmaceutical.com/press-releases...ertension/

CURE Pharmaceutical
CUREform™, a patented drug delivery platform which includes CUREfilm®, one of the most advanced oral thin films on the market today...

Important to note one of CURE's delivery system allows drugs to cross the BBB via an Oral flim....which drug does AMBS have that also crosses the BBB?
Eltoprazine does .oh, CBD also crosses the BBB
(don't forget AMBS' deal with Hempori)
https://www.globenewswire.com/news-release/20...mpori.html

I found that really interesting because
Lauren Chung, PhD is on the BOD of TODOS and was (no longer) on the board of CURE.

(That's why I believethe deal with EMOR was important. EMOR had a deal with another company PetVivo which has a film tech they were working on)

Also to note she is a
Former Partner at Yozuma
https://www.bloomberg.com/profile/person/20053925

And former BOD member on Aditxt (think TolloTest now)
https://www.businesswire.com/news/home/202106...-Directors

I think she will play a critical role in some way with Elto Pharma, Coeptis & CURE.

Other names associated and to look out for is
Modi Obochi -
With Todos moving towards a Nasdaq listing, much of our attention has focused on our subsidiary Elto Pharma’s transaction with Coeptis Pharmaceuticals, which recently hired Modi Obochi, MD MBA as Chief Executive Officer.
https://www.globenewswire.com/news-release/20...lders.html

Mike Rea - still with the 5 year deal from 2019
He was the one aligning the deal between AMBS & Coeptis at the time.
https://www.biospace.com/article/releases/ama...sidiaries/

Remeber Hempori's CBD pain cream was gaining traction a while back. Hempri is still selling products
https://www.hempori.com

I believe they will be testing Eltoprazine & CBD in combination therapy via Cure's CUREform™ Portfolio
https://curepharmaceutical.com/pharmaceutical...-delivery/
(Oral film, cream, chewable and eye drops.)

None of it was "truly" dead. (IMO) just couldn't raise any more cash and had to regroup which AMBS is doing along with Elto Pharma.

Again, very interesting to see what comes of all of this.
No coincidence things are beginning to move again with Todos quickly gaining traction and increased revenues.